JP2008540486A5 - - Google Patents

Download PDF

Info

Publication number
JP2008540486A5
JP2008540486A5 JP2008510556A JP2008510556A JP2008540486A5 JP 2008540486 A5 JP2008540486 A5 JP 2008540486A5 JP 2008510556 A JP2008510556 A JP 2008510556A JP 2008510556 A JP2008510556 A JP 2008510556A JP 2008540486 A5 JP2008540486 A5 JP 2008540486A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
roflumilast
combination product
therapeutic compound
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008510556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008540486A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2006/062117 external-priority patent/WO2006120176A2/en
Publication of JP2008540486A publication Critical patent/JP2008540486A/ja
Publication of JP2008540486A5 publication Critical patent/JP2008540486A5/ja
Withdrawn legal-status Critical Current

Links

JP2008510556A 2005-05-11 2006-05-08 Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物 Withdrawn JP2008540486A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05103938 2005-05-11
PCT/EP2006/062117 WO2006120176A2 (en) 2005-05-11 2006-05-08 Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative

Publications (2)

Publication Number Publication Date
JP2008540486A JP2008540486A (ja) 2008-11-20
JP2008540486A5 true JP2008540486A5 (https=) 2009-07-02

Family

ID=35125407

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008510556A Withdrawn JP2008540486A (ja) 2005-05-11 2006-05-08 Ｐｄｅ４インヒビター及びテトラヒドロビオプテリン誘導体との組合せ物

Country Status (14)

Country Link
US (1) US20080221111A1 (https=)
EP (1) EP1940392A2 (https=)
JP (1) JP2008540486A (https=)
KR (1) KR20080005601A (https=)
CN (1) CN101171005A (https=)
AU (1) AU2006245770A1 (https=)
BR (1) BRPI0612796A2 (https=)
CA (1) CA2607331A1 (https=)
EA (1) EA200702358A1 (https=)
IL (1) IL186804A0 (https=)
MX (1) MX2007013766A (https=)
NO (1) NO20076206L (https=)
WO (1) WO2006120176A2 (https=)
ZA (1) ZA200708776B (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518415A (ja) * 2005-12-05 2009-05-07 バイオマリン ファーマシューティカル インコーポレイテッド 疾患の処置のための方法および組成物
US20100009997A1 (en) * 2007-01-12 2010-01-14 Biomarin Pharmaceutical Inc. Method of treating a metabolic or neuropsychiarty disorder with a bh4 derivative prodrug
AU2008313660B2 (en) 2007-10-19 2013-11-07 Boehringer Ingelheim International Gmbh Substituted piperidino-dihydrothienopyrimidines
US20110144117A1 (en) * 2008-08-12 2011-06-16 Orpha Swiss Gmbh Pharmaceutical Dosage Form Containing Tetrahydrobiopterin
HUE025547T2 (en) 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
JP5629274B2 (ja) 2009-02-26 2014-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブラジキニンｂ１アンタゴニストとしての化合物
WO2010097373A1 (de) 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin b1 antagonisten
WO2010097374A1 (de) 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
CN102781916B (zh) 2010-02-23 2014-06-25 贝林格尔.英格海姆国际有限公司 作为缓激肽b1拮抗剂的化合物
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
CN102274222B (zh) * 2011-08-18 2013-04-10 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特药物组合物及其制备方法
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CN104364231A (zh) 2012-09-08 2015-02-18 塞利克斯比奥私人有限公司 用于治疗炎症和脂质异常的组合物和方法
WO2014041446A2 (en) * 2012-09-17 2014-03-20 Mahesh Kandula Compositions and methods for the treatment of metabolic diseases
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
EP3004049B1 (en) 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CN105434328A (zh) * 2014-09-01 2016-03-30 天津药物研究院有限公司 一种含罗氟司特固体分散体的固体制剂及其制备方法
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (ja) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための組成物及び方法
AU2014414316B2 (en) 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CA2973178C (en) 2015-01-06 2022-11-01 Cellix Bio Private Limited Bupivacaine derivatives and their use in the treatment of inflammation and pain
CN106176639A (zh) * 2015-04-30 2016-12-07 四川科伦药物研究院有限公司 一种制备罗氟司特片的方法
CN106139161A (zh) * 2016-08-12 2016-11-23 合肥久诺医药科技有限公司 一种罗氟司特包合物及其固体制剂
US12582809B2 (en) 2018-01-26 2026-03-24 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021213455A1 (zh) * 2020-04-23 2021-10-28 浙江养生堂天然药物研究所有限公司 药物组合及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877176A (en) * 1991-12-26 1999-03-02 Cornell Research Foundation, Inc. Blocking induction of tetrahydrobiopterin to block induction of nitric oxide synthesis
US5830461A (en) * 1992-11-25 1998-11-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Methods for promoting wound healing and treating transplant-associated vasculopathy
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
DE69725721T3 (de) * 1996-08-30 2007-10-31 Daiichi Asubio Pharma Co., Ltd. Vorbeugende oder heilende mittel für krankheiten, die durch mangel an stickoxid-synthase (nos) ausgelöst sind
SE0000307D0 (sv) * 2000-01-31 2000-01-31 Univ Zuerich Method and formulation för treatment of vasoconstriction
US6544994B2 (en) * 2000-06-07 2003-04-08 Eprov Ag Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20070049599A1 (en) * 2003-10-31 2007-03-01 Altana Pharma Ag Use of bh4 for the treatment of respiratory diseases

Similar Documents

Publication Publication Date Title
JP2008540486A5 (https=)
JP2014037426A5 (https=)
JP2014515346A5 (https=)
JP2014503574A5 (https=)
JP2010270124A5 (https=)
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
JP2012522759A5 (https=)
CR10419A (es) Derivados de Pirazolo [3,4-D]-Pirimidina útiles para tratar trastornos respiratorios
JP2013507415A5 (https=)
EP4467549A3 (en) Intermediates of n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)benzamide derivatives
JP2013519645A5 (https=)
MX2007013766A (es) Combinacion de inhibidor pde4 de roflumilast y un derivado de tetrahidrobiopterina.
JP2006520797A5 (https=)
JP2015536986A5 (https=)
JP2020521797A5 (https=)
JPWO2006035876A1 (ja) 関節リウマチの予防及び／又は治療薬
JP2013520420A5 (https=)
WO2008012290A3 (en) Quinuclidine derivatives as m3 antagonists
HK1203149A1 (en) Novel dosage form and formulation of abediterol
JP2007522162A5 (https=)
JP2017222722A5 (https=)
CA2541781A1 (en) 3-hydroxymethyl-4-hydroxy-phenyl derivatives for the treatment of respiratory illnesses
CN104203234A (zh) 吡唑衍生物用于治疗慢性阻塞性肺病急性恶化的用途
HRP20140073T1 (hr) Kombinacija rosuvastatina inhibitora reduktaze hmg-coa s inhibitorom fosfodiesteraze-4, kao što je roflumilast, roflumilast-n-oksid, za lijeäśenje pluä†nih bolesti
TW200529855A (en) Use of substituted pteridines for the treatment of respiratory diseases